DalsnaFinance › Analyst accuracy › Wells Fargo › ABBV target
Wells Fargo raises Abbvie stock price target on HS drug potential
Wells Fargo raised its price target on Abbvie stock (NYSE:ABBV) to $300 from $295 while maintaining an Overweight rating.
A fact about what Wells Fargo published, as reported by Investing.com, not a recommendation from Dalsna Finance; Wells Fargo is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.